Summary
Vertex Pharmaceuticals Inc. reported significant revenue growth in its second quarter and first half of 2016, driven primarily by strong sales of its cystic fibrosis (CF) therapies, ORKAMBI and KALYDECO. ORKAMBI, approved in mid-2015, is showing substantial traction, with revenues partially offset by patient discontinuations, though the company expects continued growth. KALYDECO also contributed to increased revenue through label expansions and broader patient access. Despite revenue growth, the company incurred net losses attributable to Vertex in both periods. Research and development expenses saw a notable increase, reflecting ongoing clinical trials and investments in future drug candidates across CF and other therapeutic areas like oncology and pain. The company also made a significant investment in CRISPR Therapeutics, underscoring its commitment to innovative technologies. Vertex maintains a healthy liquidity position with over $1 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months.
Financial Highlights
49 data points| Revenue | $431.61M |
| Cost of Revenue | $44.15M |
| Gross Profit | $387.45M |
| R&D Expenses | $271.01M |
| SG&A Expenses | $111.65M |
| Operating Expenses | $428.25M |
| Operating Income | $3.35M |
| Net Income | -$64.53M |
| EPS (Basic) | $-0.26 |
| EPS (Diluted) | $-0.26 |
| Shares Outstanding (Basic) | 244.48M |
| Shares Outstanding (Diluted) | 244.48M |
Key Highlights
- 1Total revenues surged by 160% to $431.6 million for the three months ended June 30, 2016, and by 172% to $829.7 million for the six months ended June 30, 2016, compared to the prior year periods.
- 2Product revenues were the primary driver of this growth, increasing by 165% to $425.7 million for the quarter and by 182% to $820.1 million for the six months, largely due to ORKAMBI sales which began in mid-2015.
- 3ORKAMBI generated $245.5 million in the second quarter and $468.6 million in the first half of 2016, while KALYDECO sales also increased by 16% and 23% respectively.
- 4Despite revenue increases, the company reported a net loss attributable to Vertex of $64.5 million for the quarter and $106.2 million for the six months, though this represents a significant improvement from the $188.8 million and $387.5 million losses in the respective prior year periods.
- 5Research and development expenses increased by 21% to $271.0 million for the quarter and by 20% to $526.9 million for the six months, reflecting ongoing investment in clinical trials and drug development.
- 6The company ended the period with a strong liquidity position, holding $1.07 billion in cash, cash equivalents, and marketable securities.
- 7Vertex made a significant strategic investment in CRISPR Therapeutics AG, reflecting a commitment to advanced gene-editing technologies.